No.Drug NameCompanyActive IngredientPeak Sales Estimate (million) [Fierce Biotec]2019
Sales Estimate (million)[Consensus Drug Analyst]
Date of approvalFDA-approved use on approval dateDrug Trial SnapshotFDA ClassificationsUS Approval before other countries?Classification: Biological / Chemical
1OrkambiVertex Pharmaceuticals Inclumacaftor 200 mg/ivacaftor 125 mg$5,000 $4,21907-Feb-15To treat cystic fibrosisDrug Trials SnapshotFirst-in-Class, Rare Diseases, Fast Track, Breakthrough, Priority Review, FDA used expedited development and review methodsYesChemical
2DarzalexJanssen Biotechdaratumumab$4,000 $1,40716-Nov-15To treat patients with multiple myeloma who have received at least three prior treatments.Drug Trial SnapshotFirst-in-Class, Rare Diseases, Fast Track, Breakthrough, Priority Review, Accelerated Approval, FDA used expedited development and review methodsYesBiological
3EntrestoNovartis Pharmasacubitril/valsartan$3,730 $4,00007-Jul-15To treat heart failureDrug Trials SnapshotFirst-in-Class, Fast Track, Priority Review, FDA used expedited development and review methodsYesChemical
4IbrancePfizer, Inc.palbociclib $3000 to $5000 $4,21402-Mar-15To treat advanced (metastatic) breast cancerDrug Trials SnapshotFirst-in-Class, Breakthrough, Priority Review, Accelerated Approval, FDA used expedited development and review methodsYesChemical
5TagrissoAstra Zeneca Pharmaceuticalsosimertinib$3,000 $1,07813-Nov-15To treat certain patients with non-small cell lung cancerDrug Trials SnapshotRare Diseases, Fast Track, Breakthrough, Priority Review, Accelerated Approval, FDA used expedited development and review methodsYesChemical
6TresibaNovo Nordiskinsulin degludec injection$3,000 N/A25-Sep-15To improve blood sugar (glucose) control in adults with diabetes mellitusDrug Trials SnapshotNoChemical
7RepathaAmgen Inc.evolocumab$3,000 $2,04227-Aug-15To treat certain patients with high cholesterolDrug Trials SnapshotRare DiseasesNoBiological
8PraluentSanofi-Aventis U.S.alirocumab$3,000 $1,98024-Jul-15To treat certain patients with high cholesterolDrug Trials SnapshotFirst-in-ClassYesBiological
9CosentyxNovartis Pharmaceuticals Corporation.secukinumab$1,800 $1,81921-Jan-15To treat adults with moderate-to-severe plaque psoriasisDrug Trials SnapshotFirst-in-ClassNoBiological
10NinlaroTakeda Pharmaceuticalsixazomib$1,500 $1,24120-Nov-15To treat people with multiple myeloma who have received at least one prior therapyDrug Trials SnapshotRare Diseases, Priority Review, FDA used expedited development and review methodsYesChemical
11UptraviActelion Pharmaceuticals US, Inc.selexipag$1,400 $94122-Dec-15To treat pulmonary arterial hypertensionDrug Trial SnapshotRare DiseasesYesChemical
12RexultiOtsuka Pharmaceutical Company Ltdbrexpiprazole$1,400 $92207-Oct-15To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorderDrug Trials Snapshot (treatment of major depressive disorder), Drug Trials Snapshot (treatment of schizophrenia)YesChemical
13VeltassaRelypsa Inc.patiromer for oral suspension$1,000 N/A21-Oct-15To treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.Drug Trials SnapshotYesChemical
14AvycazForest Laboratories, Inc.ceftazidime-avibactam$1,000 N/A25-Feb-15To treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options.Drug Trials Snaphot (cIAI), Drug Trials Snapshot (cUTI) Fast Track, Priority Review, FDA used expedited development and review methods, Qualified Infectious Disease Program DesignationsYesChemical
15KanumaAlexion Pharmaceuticals Incsebelipase alfa$800 to $1500 $53812-Aug-15To treat patients with a rare disease known as lysosomal acid lipase (LAL) deficiencyFirst-in-Class, Rare Diseases, Fast Track, Breakthrough, Priority Review, FDA used expedited development and review methodsNoBiological
16CotellicGenentechcobimetinib$800 $28111-Oct-15To be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation)Drug Trials SnapshotRare Diseases, Fast Track, Priority Review, FDA used expedited development and review methodsNoChemical
17OdomzoNovartis Pharmaceuticals Corporationsonidegib$800 $19024-Jul-15To treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy.Drug Trials SnapshotNoChemical
18NucalaGlaxoSmithKlinemepolizumab$600 to $1000 £50011-Apr-15For use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older.First-in-ClassYesBiological
19AristadaAlkermes, Incaripiprazole lauroxil$550 $36210-Jun-15To treat adults with schizophreniaDrug Trials SnapshotYesChemical
20ZurampicArdea Biosciences INC. lesinurad$500 $38022-Dec-15To treat high blood uric acid levels associated with goutYesChemical
21StrensiqAlexion Pharmaceuticals Inc.asfotase alfa$500 $35223-Oct-15To treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP).Drug Trials SnapshotFirst-in-Class, Rare Diseases, Fast Track, Breakthrough, Priority Review, FDA used expedited development and review methodsNoBiological
22Cresemba capsule injectionAstellas Pharma US, Inc.isavuconazonium sulfate$500 $7203-Jun-15To treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infectionsDrug Trials Snapshot (aspergillosis), Drug Trials Snapshot (mucormycosis) Rare Diseases, Priority Review, FDA used expedited development and review methods, Qualified Infectious Disease Program DesignationsYesChemical
23NatparaNPS Pharmaceuticals, Inc.parathyroid horomone$500 $56823-Jan-15To control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidismDrug Trials SnapshotRare DiseasesYesBiological
24PortrazzaEli Lilly and Companynecitumumab$450 $55124-Nov-15To treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancerDrug Trial SnapshotRare Diseases, Fast Track, FDA used expedited development and review methodsYesBiological
25Kengreal The Medicines Companycanegrelor$440 $9522-Jun-15To prevent the formation of harmful blood clots in the coronary arteries for adult patients undergoing percutaneous coronary interventionDrug Trials SnapshotNoChemical
26ViberziForest Pharmaceuticals, Inceluxadoline$440 N/A27-May-15To treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women.Drug Trials SnapshotFast Track, Priority Review, FDA used expedited development and review methodsYesChemical
27LenvimaEisai Inclenvatinib$424 $72813-Feb-15To treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease).Drug Trials SnapshotRare Diseases, Priority Review, FDA used expedited development and review methodsYesChemical
28VarubiTesaro Inc.rolapitant$400 N/A9-Feb-15To prevent delayed phase chemotherapy-induced nausea and vomiting (emesis)Drug Trials SnapshotYesChemical
29YondelisJanssen trabectedin$330 N/A23-Oct-15To treat specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic).Drug Trials SnapshotRare Diseases, Priority Review, FDA used expedited development and review methodsNoChemical
30Corlanor Amgen Incivabradine$300 to $1000 $30015-Apr-15To reduce hospitalization from worsening heart failure.Drug Trials SnapshotFirst-in-Class, Fast Track, Priority Review, FDA used expedited development and review methodsNoChemical
31EmplicitiBristol-Myers Squibbelotuzumab$300 $67930-Nov-15To treat people with multiple myeloma who have received one to three prior medicationsDrug Trials SnapshotFirst-in-Class, Rare Diseases, Breakthrough, Priority Review, FDA used expedited development and review methodsYesBiological
32KybellaKythera Biopharmaceuticals Inc.deoxycholic acid$300 $40829-Apr-15To treat adults with moderate-to-severe fat below the chin, known as submental fatDrug Trials SnapshotYesChemical
33BridionMerck Sharp and Dohme Corp.sugammadex$270 $70215-Dec-15To reverse effects of neuromuscular blocking drugs used during surgeryDrug Trials SnapshotFirst-in-Class, Priority Review, FDA used expedited development and review methodsNoChemical
34FarydakNovartis Pharmaceuticals.panobinostat$250 N/A23-Feb-15To treat patients with multiple myelomaDrug Trials SnapshotRare Diseases, Priority Review, Accelerated Approval, FDA used expedited development and review methodsYesChemical
35SavaysaDaiichi Sankyoedoxaban$220 $5928-Jan-15To reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problemDrug Trials Snapshot (atrial fibrillation), Drug Trials Snapshot (venous thromboembolism)NoChemical
36VraylarForest Laboratories LLCcariprazine$200 to $300 N/A17-Sep-15To treat schizophrenia and bipolar disorder in adultsDrug Trials SnapshotYesChemical
37AddyiSprout Pharmaceuticalsflibanserin$100 to $300N/A18-Aug-15To treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal womenDrug Trials SnapshotFirst-in-ClassYesChemical
38UnituxinUnited Therapeuticsdinutuximab $60 to $150 $8503-Oct-15To treat pediatric patients with high-risk neuroblastomaDrug Trials SnapshotFirst-in-Class, Rare Diseases, Priority Review, FDA used expedited development and review methodsYesBiological
39GenvoyaGilead Sciences Inc.a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine and $4,22311-May-15For use as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and olderDrug Trials SnapshotFast Track, FDA used expedited development and review methodsYesChemical
40AlecensaGenentechalectinibN/A$31712-Nov-15To treat ALK-positive lung cancerDrug Trial SnapshotRare Diseases, Breakthrough, Priority Review, Accelerated Approval, FDA used expedited development and review methodsNoChemical
41PraxbindBoehringer IngelheimidarucizumabN/AN/A16-Oct-15For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.Drug Trials SnapshotFirst-in-Class, Rare Diseases, Breakthrough, Priority Review, Accelerated Approval, FDA used expedited development and review methodsYesBiological
42LonsurfTaiho Oncology Inctrifluridine and tipiracilN/A$18422-Sep-15To treat patients with an advanced form of colorectal cancer who are no longer responding to other therapiesDrug Trials SnapshotFast Track, FDA used expedited development and review methodsNoChemical
43XuridenWellstat Therapeutics Corporationuridine triacetateN/AN/A9-Apr-15To treat patients with hereditary orotic aciduriaDrug Trials SnapshotFirst-in-Class, Rare Diseases, Breakthrough, Priority Review, FDA used expedited development and review methodsYesChemical
44DaklinzaBristol-Myers SquibbdaclatasvirN/AN/A24-Jul-15To treat chronic hepatitis C virus (HCV) genotype 3 infectionsDrug Trials SnapshotFast Track, Priority Review, FDA used expedited development and review methodsNoChemical
45CholbamAsklepion Pharmaceuticals LLC.cholic acidN/AN/A17-Mar-15To treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disordersDrug Trials Snapshot (bile acid synthesis disorders), Drug Trials Snapshot (peroxisomal disorders)Rare Diseases, Priority Review, FDA used expedited development and review methodsNoChemical